Association of IL-10 rs1800871 and rs1800872 Polymorphisms with Breast Cancer Risk: A Systematic Review and Meta-Analysis

Abstract

Background: The rs1800871 and rs1800872 polymorphisms of interleukin 10 (IL-10) gene has been indicated to be associated with breast cancer (BC) risk, but study results are still debatable. To derive a more precise evaluation, we performed a comprehensive meta-analysis. Methods: Multiple electronic databases were searched to identify studies assessing the IL-10 rs1800871 and rs1800872 polymorphisms with BC risk. Results: A total of 21 case-control studies with 6054 cases and 6355 controls were included in this met-analysis. There was a significant association between the rs1800871 polymorphism and BC risk (CT vs. TT: OR= 1.17, 95% CI 1.01-1.35, p=0.02; and CC+CT vs. TT: OR= 1.29, 95% CI 1.00-1.66, p=0.04). Moreover, increased BC risks were also associated with the rs1800872 polymorphism (C vs. A: OR= 1.29, 95% CI 1.04-1.60, p=0.01; CC vs. AA: OR= 1.54, 95% CI 1.03-2.30, p=0.03; CC+CA vs. AA: OR= 1.43, 95% CI 1.01-2.01, p=0.03; and CC vs. CA+AA: OR= 1.23, 95% CI 1.01-1.51, p=0.04). A pooling of the studies was also conducted by ethnicity, but failed to show an association of IL-10 rs1800871 and rs1800872 polymorphism with BC risk in Asians and Caucasians. Conclusions: Our results are inconsistent with previous meta-analysis suggests that IL-10 rs1800871 and rs1800872 polymorphisms might contribute to BC susceptibility in overall population, but not by ethnicity.

Expression of MTDH and IL-10 Is an Independent Predictor of Worse Prognosis in ER-Negative or PR-Negative Breast Cancer Patients

“…In contrast, multivariate analysis demonstrated that a higher IL-10 level is associated with worse disease conditions, including late-stage, ER-negative, and PR-negative breast cancer in our study. A systematic review and meta-analysis revealed that the rs1800871 and rs1800872 polymorphisms of the IL-10 gene are associated with overall breast cancer risk in the general population [ 25 ]. We speculate that IL-10 expression in breast cancer may serve as a preferential metastatic condition that permits cells to evade host anticancer immunity, which is dependent on the ER and PR status.…”

The single nucleotide polymorphisms of interleukin-10 are associated with the risk of leukaemia

“…[ 36 – 38 ] It has been reported that polymorphisms in the promoter region of IL-10 may influence the production of IL-10. [ 39 ] There are many studies and systematic analyses reporting the association between SNPs of IL-10 and other cancers, including gastric cancer40, [ 40 ] cervical cancer, [ 41 ] breast cancer, [ 42 ] and prostate cancer. [ 43 ]…”

IL10 as Cancer Biomarker

“…After meta-analysis, it showed that IL10 rs1800896 and rs1800871 polymorphisms had no association with breast cancer risk, while rs1800872 polymorphism had a decreased risk of breast cancer in Caucasians [3]. However, another meta-analysis suggests that IL10 rs1800871 and rs1800872 polymorphisms might contribute to breast cancer susceptibility in the overall population, but not by ethnicity [6].…”

“…It presents polymorphisms (SNPs), most of them within the promoter regions, and has been proposed as responsible for the altered function, by dysregulating their expression. Several groups report associations between polymorphism and cancer risk [3][4][5][6][7]. It is a helical cytokine and exists in solution predominantly as a homodimer, composed of two polypeptide chains of 160 amino acids, each with a molecular weight of 20,6419 kD [8].…”